US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of VYN201 gel, known as repibresib, for treating non-segmental vitiligo.
BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical ...
VYNE will use the name repibresib in public statements, at conferences and other forums, and in corporate-related materials as the Company continues to advance the clinical development of the product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback